68Ga-LNC-1007 PET/CT与68Ga-PSMA-11 PET/CT在肾细胞癌患者中的显像比较
一名57岁男性因偶然发现双肾3个病灶,术后病理确诊为肾细胞癌。68Ga-LNC-1007(即68Ga-FAPI-RGD)由成纤维细胞活化蛋白抑制剂-02(FAPI-02)与环状精氨酸-甘氨酸-天冬氨酸(RGD)合成,可同时靶向FAP与整合素αvβ3。肾细胞癌病灶在68Ga-PSMA PET/CT上仅见轻度摄取,但在68Ga-LNC-1007 PET/CT上呈强烈示踪剂摄取,提示68Ga-LNC-1007 PET/CT对肾细胞癌评估具有潜在价值。
要点
- 57岁男性双肾3个病灶,术后病理确诊为肾细胞癌。
- 68Ga-LNC-1007(68Ga-FAPI-RGD)可同时靶向FAP与整合素αvβ3。
- 肾细胞癌病灶68Ga-PSMA摄取仅轻度,68Ga-LNC-1007 PET/CT摄取强烈。
核心结论
- 本病例提示68Ga-LNC-1007 PET/CT对肾细胞癌的评估具有潜在价值。
研究设计与样本
- 个案报道:一名57岁男性,偶然发现双肾3个病灶,术后病理确诊为肾细胞癌,行68Ga-LNC-1007 PET/CT并与68Ga-PSMA-11 PET/CT比较。
主要发现
- 肾细胞癌病灶在68Ga-PSMA PET/CT上仅见轻度示踪剂摄取。
- 肾细胞癌病灶在68Ga-LNC-1007 PET/CT上呈强烈示踪剂摄取。
关键数值与推荐
- 68Ga-LNC-1007又称68Ga-FAPI-RGD,由FAPI-02与环状RGD合成,可同时靶向FAP与整合素αvβ3。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 57-year-old man was incidentally found with 3 lesions located in bilateral kidneys, which were finally diagnosed as renal cell carcinoma (RCC) by postoperative pathology. 68 Ga-LNC-1007, also denoted as 68 Ga-FAPI-RGD, was synthesized from fibroblast activation protein inhibitor-02 (FAPI-02) and cyclic arginine-glycine-aspartate (RGD), which could target both FAP and integrin α v β 3 . RCC lesions demonstrated only slight 68 Ga-PSMA uptake, but intense tracer uptake on 68 Ga-LNC-1007 PET/CT. This case demonstrates the potential value of 68 Ga-LNC-1007 PET/CT for the evaluation of RCC.
引用
- Lin R, Wang C, Xu F, et al. 68 Ga-LNC-1007 PET/CT Imaging in a Patient With Renal Cell Carcinoma Compared With 68 Ga-PSMA-11 PET/CT. Clin Nucl Med. 2023. PMID: 37844334. doi:10.1097/RLU.0000000000004881
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。